Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    SNCA
Show Display Options
Rank Status Study
1 Recruiting Oligomeric Alpha-synuclein in Multiple System Atrophy
Condition: Multiple System Atrophy (MSA)
Intervention:
2 Active, not recruiting Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Condition: Parkinson's Disease
Intervention: Drug: Glycerol Phenylbutyrate
3 Unknown  Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.
Condition: "Alzheimer's Disease" and "Lewy Body Disease"
Interventions: Other: MRI;   Procedure: lumbar puncture;   Behavioral: neuropsychological tests
4 Active, not recruiting Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Conditions: Parkinson Disease;   Parkinsonian Disorders
Intervention: Procedure: Biopsy of skin
5 Recruiting Biomarkers in Parkinsonian Syndromes
Conditions: Parkinsonian Syndromes;   Parkinson's Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Interventions: Other: CSF, blood and urine sampling;   Other: clinical measures of disease severity and progression
6 Completed Analysis of the Enteric Nervous System Using Colonic Biopsies
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention: Procedure: colonoscopy or rectosigmoidoscopy
7 Completed GALIG Gene Expression in Parkinson's Disease
Condition: Parkinson Disease
Intervention: Other: Blood sampling
8 Unknown  Diagnostic and Prognostic Biomarkers in Parkinson Disease
Conditions: Parkinson Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention:
9 Recruiting Systemic Synuclein Sampling Study (S4)
Condition: Parkinson's Disease
Interventions: Procedure: Biofluid samplings;   Procedure: Tissue samplings;   Drug: DaTSCAN™
10 Terminated Early Parkinson's Disease (PD) Cross-Sectional
Condition: Parkinson's Disease
Intervention:
11 Withdrawn Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Condition: Parkinson's Disease
Interventions: Biological: AFFITOPE® PD01A + Adjuvant;   Biological: Adjuvant without active component
12 Recruiting Natural History Study of Synucleinopathies
Condition: Patients With Synucleinopathies
Intervention:
13 Not yet recruiting Enteric Nervous System in Alzheimer Disease
Condition: Alzheimer Disease
Interventions: Procedure: Rectosigmoidoscopy with colonic biopsies;   Procedure: Colonoscopy with colonic biopsies
14 Terminated Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
Condition: Parkinson's Disease
Intervention: Other: colonoscopy or rectosigmoidoscopy
15 Not yet recruiting Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Conditions: Parkinson Disease;   Parkinsons Disease With Dementia
Interventions: Drug: Placebo Oral Capsule;   Drug: Nilotinib 150mg oral capsule [Tasigna];   Drug: Nilotinib 300mg oral capsule [Tasigna]
16 Completed Biological Markers in Parkinson's Disease
Condition: Parkinson Disease
Intervention:
17 Recruiting Ambroxol as a Treatment for Parkinson's Disease Dementia
Condition: Parkinson's Disease Dementia
Interventions: Drug: Ambroxol;   Other: Placebo
18 Active, not recruiting Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment
Condition: Autonomic Disturbances in Parkinson`s Disease
Interventions: Drug: Pyridostigmine bromide;   Drug: fludrocortisone
19 Unknown  Clinical, Molecular and by Neuroimaging of LRRK2 Mutations
Condition: Parkinson's Disease
Intervention:
20 Active, not recruiting Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
Conditions: Parkinson's Disease;   HIV Infections
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.